Company: LHI
Filing Date: 2025-08-08
Form Type: F-1/A
Source: 0001213900-25-073646
Chunk: 244

Company: Living Homeopathy International Ltd.
Filing Date: 2025-08-08
Form: F-1/A
Chunk 244
---
 ASC 360-10-15. To the extent that estimated future undiscounted cash inflows attributable to the asset, less estimated future
undiscounted cash outflows, are less than the carrying amount, an impairment loss is recognized in an amount equal to the difference
between the carrying value of such an asset and its fair value. Assets to be disposed of and for which there is a committed plan of disposal,
whether through sale or abandonment, are reported at the lower of carrying value or fair value less costs to sell. There were no impairments
of these assets as of March 31, 2025 and 2024.

The Company utilizes ASC 842 to account for
leases for all periods presented.

The Company determines if an arrangement is
a lease at inception. On the Company’s consolidated balance sheets, right-of-use (“ROU”) assets, current portion of
lease liabilities, and non-current portion of lease liabilities are accounted.

ROU assets and lease liabilities are recognized
based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company’s leases
do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date
in determining the present value of future payments. The ROU asset also includes any lease payments made and initial direct costs incurred
and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably
certain that the Company will exercise that option. For leases that have lease terms of 12 months or less and does not include a purchase
option that is reasonably certain to exercise, the Company elected not to apply ASC 842 recognition requirements. Lease expenses for
minimum lease payments are recognized on a straight-line basis over the lease term. Any lease with a term of 12 months or less is considered
short-term.

<div align='center'>F-10</div>

The Company follows the requirements of the
FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A — “Expenses of Offering”. Deferred
offering costs consist of underwriting, legal and other expenses incurred through the balance sheet date that are directly related to
the intended initial public offering (“IPO”). Deferred offering costs will be charged to shareholders’ equity netted
against the proceeds upon the completion of the IPO. Should the IPO prove to be unsuccessful, these deferred costs, as well as additional
expenses